Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Receivables (2016 - 2025)

Historic Receivables for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $13.9 million.

  • Iradimed's Receivables rose 3370.55% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 3370.55%. This contributed to the annual value of $10.6 million for FY2024, which is 1364.12% down from last year.
  • As of Q3 2025, Iradimed's Receivables stood at $13.9 million, which was up 3370.55% from $10.9 million recorded in Q2 2025.
  • Iradimed's 5-year Receivables high stood at $13.9 million for Q3 2025, and its period low was $3.9 million during Q2 2021.
  • Its 5-year average for Receivables is $9.9 million, with a median of $10.9 million in 2025.
  • Its Receivables has fluctuated over the past 5 years, first crashed by 2200.45% in 2021, then soared by 15843.02% in 2022.
  • Over the past 5 years, Iradimed's Receivables (Quarter) stood at $5.1 million in 2021, then surged by 158.43% to $13.3 million in 2022, then decreased by 7.91% to $12.2 million in 2023, then decreased by 13.64% to $10.6 million in 2024, then surged by 31.27% to $13.9 million in 2025.
  • Its last three reported values are $13.9 million in Q3 2025, $10.9 million for Q2 2025, and $12.7 million during Q1 2025.